Nurse Practitioner Certification
q q q
Examination and Practice Preparation
q q q q q
Testbank by Margaret A. Fitzgerald
q q q q q
,Health Promotion
1
q
and Disease Prevention
q q
6. Active q immunity q is q defined q as:
A. resistance q developed q in q response q to q an q antigen.
B. immunity qconferred qby qan qantibody qproduced
qin qanother qhost.
1. An qexample qof qa qprimary qprevention qmeasure qfor C. the qresistance qof qa qgroup qto qan qinfectious qagent.
qa78- qyear-old q man q with qchronic q obstructive
D. defense qagainst qdisease qacquired qnaturally qby qthe
q pulmonary qdisease qis:
qinfant qfrom qthe qmother.
A. reviewing q the q use q of q prescribed q medications.
B. conducting q a q home q survey q to q minimize q fall q risk. 7. Which qof qthe qfollowing qis qusually qviewed qas qthe
C. checking qFEV1 q(force qexpired qvolume qat q1 qsecond) qmost qcost-effective qform qof qhealthcare?
qto qFVC q(forced qvital qcapacity) qratio. A. primary q prevention
D. ordering qfecal qoccult qblood qtest q(FOBT). B. secondary q prevention
C. tertiary q prevention
2. Which qof qthe qfollowing qis qan qexample qof qa qprimary D. cancer-reduction q measures
qpreven- qtion qactivity qin qa q76-year-old qwoman qwith
qosteoporosis? 8. An q18-year-old qwoman qwith qallergic qrhinitis qpresents
A. bisphosphonate q therapy qfor qprimary qcare. qShe qis qsexually qactive qwith qa qmale
B. calcium q supplementation qpartner qand qis q1 qyear qpost-coitarche; qduring qthis qtime
C. ensuring qadequate qillumination qin qthe qhome qshe qhad qhad qtwo qsex qpartners. qAn qexample qof qa
D. use qof qa qback qbrace qprimary qprevention qactivity qfor qthis qpatient qis:
A. screening q for q sexually q transmitted q infection.
3. Secondary qprevention qmeasures qfor qa q78-year-old B. counseling q about q safer q sexual q practices.
qman qwith qchronic qobstructive qpulmonary qdisease
C. prescribing q therapies q for q minimizing q allergy.
qinclude:
D. obtaining q a q liquid-based q Papanicolaou q (Pap) q test.
A. screening qfor qmood qdisorders.
B. administering q influenza q vaccine. 9. When qa qcritical qportion qof qa qcommunity qis
C. obtaining q a q serum q theophylline q level. qimmunized qagainst qa qcontagious qdisease, qmost
D. advising qabout qappropriate quse qof qcar qpassenger qmembers qof qthe qcom- qmunity, qeven qthe
qrestraints. qunimmunized, qare qprotected qagainst qthat qdisease
qbecause qthere qis qlittle qopportunity qfor qan qoutbreak.
4. Tertiary qprevention qmeasures qfor qa q69-year-old qThis qis qknown qas immunity.
qwoman qwith qheart qfailure qinclude:
A. passive
A. administering q antipneumococcal q vaccine. B. humoral
B. adjusting q therapy q to q minimize q dyspnea. C. epidemiologic
C. surveying q skin q for q precancerous q lesions. D. community
D. reviewing q safe q handling q of q food.
5. Which q of q the q following q products q provides q passive
immunity?
A. qhepatitis qB qimmune qglobulin q(HBIG)
Answers
B. qmeasles, qmumps, qand qrubella q(MMR) qvaccine 1. q B. 4. q B. 7. q A.
C. qpneumococcal qconjugate qvaccine 2. q C. 5. q A. 8. q B.
D. qlive qattenuated qinfluenza qvaccine q(LAIV) 3. q A. 6. q A. 9. q D.
1
,2 C qH qA qP qT qEqR q q 1 ■ q q Health q Promotion q and q Disease q Prevention
Primary qprevention qmeasures qinclude qactivities
qprovided qto qindividuals qto qprevent qthe qonset qor
qacquisition qof qa qgiven qdisease. qThe qgoal qof qprimary
qprevention qmeasures qis qto qspare qindividuals qthe qsuffering,
qburden, qand qcost qassociated qwith qthe
clinical qcondition qand qis qthe qfirst qlevel qof qhealthcare. qAn qDisease qControl qand qPrevention: qLevels qof qPrevention
qex- qample qis qhealth-protecting qeducation qand qcounseling, http://www.niaid.nih.gov/topics/pages/communityimmunity.aspx,
qsuch qas qencouraging qthe quse qof qcar qrestraints qand q National qInstitute qof qAllergy qand qInfectious qDisease:
qCommunity qImmunity
qbicycle qhelmets, qcounseling qabout qsafer qsexual qpractices,
qand qproviding qinfor- qmation qon qaccident qand qfall
qprevention. qGiven qits qfocus qon qpreventing qillness qor
qinjury, qprimary qprevention qis qusually qviewed qas qthe
qmost qeffective qform qof qhealthcare.
Immunizations qand qchemoprophylaxis qare qalso
qexam- qples qof qprimary qprevention qmeasures. qActive
qimmunization qthrough qthe quse qof qvaccines qprovides qlong-
term qprotection qfrom qdisease. qIn qherd qor qcommunity
qimmunity, qa qsignificant qportion qof qa qgiven qpopulation qhas
qimmunity qagainst qan qinfec- qtious qagent; qthe qlikelihood qthat
qthe qsusceptible qportion qof qthe qgroup qwould qbecome
qinfected qis qminimized q(Fig. q1–1). qPas- qsive qimmunity qis
qprovided qwhen qa qperson qreceives qselect qan- qtibodies,
qusually qvia qthe qadministration qof qimmune qglobulin q(IG),
qafter qexposure qto qan qinfective qagent. qThis qimmunity qis
qtemporary qand qrequires qthe qpatient qto qpresent qpost-
exposure; qthe qprotection qprovided qby qIG qusually qstarts
qwithin qhours qof qreceiving qthe qdoses qand qlasts qa qnumber qof
qmonths. qThe quse qof qvaccines qto qproduce qlasting qdisease
qprotection qis qpreferred qto qpassive qimmunization qthrough
qthe quse qof qIG. qAnother qexam- qple qof qpassive qimmunity qis
qthe qacquisition qof qdisease qprotec- qtion qprovided qfrom
qmother qto qunborn qchild qvia qthe qplacenta. qSecondary
qprevention qmeasures qinclude qactivities qprovided qto
qidentify qand qtreat qasymptomatic qpersons qwho qhave qrisk qfac-
qtors qfor qa qgiven qdisease qor qin qpreclinical qdisease. qExamples
qin- qclude qscreening qexaminations qfor qpreclinical
qevidence qof qcancer, qsuch qas qmammography qand qcervical
qexamination qwith q a qPapanicolaou qtest. qOther qexamples qof
qsecondary qprevention qactivities qinclude qscreening qfor
qclinical qconditions qwith qa qpro- qtracted qasymptomatic
qperiod, qsuch qas qa qblood qpressure qmeas- qurement qto qdetect
qhypertension qand qa qlipid qprofile qto qdetect
qhyperlipidemia q(Table q1–1).
See qfull qcolor qimages qof qthis qtopic
qon qDavisPlus qat
qhttp://davisplus.fadavis.com q|
qKeyword: qFitzgerald
Tertiary qprevention qmeasures qare qpart qof qthe
qmanagement qof qan qestablished qdisease. qThe qgoal qis qto
qminimize qdisease- qassociated qcomplications qand qthe
qnegative qhealth qeffects qof qthe qconditions qto qthe qpatient.
qExamples qinclude qmedications qand qlifestyle qmodification
qto qnormalize qblood qglucose qlevels qin qindividuals qwith
qdiabetes qmellitus qand qin qconjunction qwith qthe qtreatment qof
qheart qfailure, qaimed qat qimproving qor qmini- qmizing
qdisease-related qsymptoms.
DISCUSSION q SOURCES
http://www.cdc.gov/excite/skincancer/mod13.htm, Centers for
, 10. When qadvising qa qpatient qabout qinjectable qinfluenza C. The q drugs q are q active q only q against q influenza q B.
qim- qmunization, qthe qnurse qpractitioner q(NP) D. The quse qof qthese qmedications qis qan qacceptable
qconsiders qthe qfollowing qabout qthe quse qof qthis qalter- qnative qto qinfluenza qvaccine.
qvaccine:
A. Its quse qis qnot qrecommended qin qsickle qcell qanemia.
B. Its quse qis qlimited qto qchildren qolder qthan q2 qyears.
C. Its q use q is q limited q due q to q containing q live q virus.
D. Its quse qis qrecommended qfor qvirtually qall qmembers
qof qthe qpopulation.
11. A qmiddle-aged qman qwith qchronic qobstructive
qpul- qmonary qdisease qwho qis qabout qto qreceive
qinjectable qin- qfluenza qvaccine qshould qbe
qadvised qthat:
A. it qis qmore qthan q90% qeffective qin qpreventing
qinfluenza.
B. its quse qis qcontraindicated qin qthe qpresence qof
qpsoriasis qvulgaris.
C. localized qreactions qsuch qas qsoreness qand qredness
qat qthe qsite qof qthe qimmunization qare qfairly
qcommon.
D. a qshort, qintense, qflulike qsyndrome qtypically
qoccurs qafter qimmunization.
12. A q44-year-old qwoman qwith qasthma qpresents qasking
qfor qa q“flu qshot.” qShe qis qseen qtoday qfor qan qurgent qcare
qvisit, qis qdiagnosed qwith qa qlower qurinary qtract
qinfection, qand qis qprescribed qtrimethoprim-
sulfamethoxazole. qShe qis qwithout qfever qor
qgastrointestinal qupset qwith qstable qrespiratory
qstatus. qYou qinform qher qthat qshe:
A. should qreturn qfor qthe qimmunization qafter
qcomplet- qing qher qantibiotic qtherapy.
B. would qlikely qdevelop qa qsignificant qreaction qif
qimmu- qnized qtoday.
C. can q receive q the q immunization q today.
D. is qnot qa qcandidate qfor qany qform qof qinfluenza
qvaccine.
13. Which qof qthe qfollowing qstatements qbest qdescribes
qamantadine qor qrimantadine quse qin qthe qcare qof
qpatients qwith qor qat qrisk qfor qinfluenza?
A. Significant qresistance qto qselect qstrains qof
qinfluenza qlimits qthe qusefulness qof qthese
qmedications.
B. The qprimary qaction qof qthese qtherapies qis qin
qprevent- qing qinfluenza qA qduring qoutbreaks.
C. These q therapies q are q active q against q influenza q A q and
q B.
D. The quse qof qthese qproducts qis qan qacceptable
qalternative qto qinfluenza qvaccine.
14. Which qof qthe qfollowing qstatements qbest qdescribes
qzanamivir q(Relenza) qor qoseltamivir q(Tamiflu) quse qin
qthe qcare qof qpatients qwith qor qat qrisk qfor qinfluenza?
A. Initiation qof qtherapy qearly qin qacute qinfluenza
qillness qcan qhelp qminimize qthe qseverity qof qdisease
qwhen qthe qillness qis qcaused qby qa qnonresistant
qviral qstrain.
B. The qprimary qindication qis qin qpreventing qinfluenza
qA qduring qoutbreaks.
q q q
Examination and Practice Preparation
q q q q q
Testbank by Margaret A. Fitzgerald
q q q q q
,Health Promotion
1
q
and Disease Prevention
q q
6. Active q immunity q is q defined q as:
A. resistance q developed q in q response q to q an q antigen.
B. immunity qconferred qby qan qantibody qproduced
qin qanother qhost.
1. An qexample qof qa qprimary qprevention qmeasure qfor C. the qresistance qof qa qgroup qto qan qinfectious qagent.
qa78- qyear-old q man q with qchronic q obstructive
D. defense qagainst qdisease qacquired qnaturally qby qthe
q pulmonary qdisease qis:
qinfant qfrom qthe qmother.
A. reviewing q the q use q of q prescribed q medications.
B. conducting q a q home q survey q to q minimize q fall q risk. 7. Which qof qthe qfollowing qis qusually qviewed qas qthe
C. checking qFEV1 q(force qexpired qvolume qat q1 qsecond) qmost qcost-effective qform qof qhealthcare?
qto qFVC q(forced qvital qcapacity) qratio. A. primary q prevention
D. ordering qfecal qoccult qblood qtest q(FOBT). B. secondary q prevention
C. tertiary q prevention
2. Which qof qthe qfollowing qis qan qexample qof qa qprimary D. cancer-reduction q measures
qpreven- qtion qactivity qin qa q76-year-old qwoman qwith
qosteoporosis? 8. An q18-year-old qwoman qwith qallergic qrhinitis qpresents
A. bisphosphonate q therapy qfor qprimary qcare. qShe qis qsexually qactive qwith qa qmale
B. calcium q supplementation qpartner qand qis q1 qyear qpost-coitarche; qduring qthis qtime
C. ensuring qadequate qillumination qin qthe qhome qshe qhad qhad qtwo qsex qpartners. qAn qexample qof qa
D. use qof qa qback qbrace qprimary qprevention qactivity qfor qthis qpatient qis:
A. screening q for q sexually q transmitted q infection.
3. Secondary qprevention qmeasures qfor qa q78-year-old B. counseling q about q safer q sexual q practices.
qman qwith qchronic qobstructive qpulmonary qdisease
C. prescribing q therapies q for q minimizing q allergy.
qinclude:
D. obtaining q a q liquid-based q Papanicolaou q (Pap) q test.
A. screening qfor qmood qdisorders.
B. administering q influenza q vaccine. 9. When qa qcritical qportion qof qa qcommunity qis
C. obtaining q a q serum q theophylline q level. qimmunized qagainst qa qcontagious qdisease, qmost
D. advising qabout qappropriate quse qof qcar qpassenger qmembers qof qthe qcom- qmunity, qeven qthe
qrestraints. qunimmunized, qare qprotected qagainst qthat qdisease
qbecause qthere qis qlittle qopportunity qfor qan qoutbreak.
4. Tertiary qprevention qmeasures qfor qa q69-year-old qThis qis qknown qas immunity.
qwoman qwith qheart qfailure qinclude:
A. passive
A. administering q antipneumococcal q vaccine. B. humoral
B. adjusting q therapy q to q minimize q dyspnea. C. epidemiologic
C. surveying q skin q for q precancerous q lesions. D. community
D. reviewing q safe q handling q of q food.
5. Which q of q the q following q products q provides q passive
immunity?
A. qhepatitis qB qimmune qglobulin q(HBIG)
Answers
B. qmeasles, qmumps, qand qrubella q(MMR) qvaccine 1. q B. 4. q B. 7. q A.
C. qpneumococcal qconjugate qvaccine 2. q C. 5. q A. 8. q B.
D. qlive qattenuated qinfluenza qvaccine q(LAIV) 3. q A. 6. q A. 9. q D.
1
,2 C qH qA qP qT qEqR q q 1 ■ q q Health q Promotion q and q Disease q Prevention
Primary qprevention qmeasures qinclude qactivities
qprovided qto qindividuals qto qprevent qthe qonset qor
qacquisition qof qa qgiven qdisease. qThe qgoal qof qprimary
qprevention qmeasures qis qto qspare qindividuals qthe qsuffering,
qburden, qand qcost qassociated qwith qthe
clinical qcondition qand qis qthe qfirst qlevel qof qhealthcare. qAn qDisease qControl qand qPrevention: qLevels qof qPrevention
qex- qample qis qhealth-protecting qeducation qand qcounseling, http://www.niaid.nih.gov/topics/pages/communityimmunity.aspx,
qsuch qas qencouraging qthe quse qof qcar qrestraints qand q National qInstitute qof qAllergy qand qInfectious qDisease:
qCommunity qImmunity
qbicycle qhelmets, qcounseling qabout qsafer qsexual qpractices,
qand qproviding qinfor- qmation qon qaccident qand qfall
qprevention. qGiven qits qfocus qon qpreventing qillness qor
qinjury, qprimary qprevention qis qusually qviewed qas qthe
qmost qeffective qform qof qhealthcare.
Immunizations qand qchemoprophylaxis qare qalso
qexam- qples qof qprimary qprevention qmeasures. qActive
qimmunization qthrough qthe quse qof qvaccines qprovides qlong-
term qprotection qfrom qdisease. qIn qherd qor qcommunity
qimmunity, qa qsignificant qportion qof qa qgiven qpopulation qhas
qimmunity qagainst qan qinfec- qtious qagent; qthe qlikelihood qthat
qthe qsusceptible qportion qof qthe qgroup qwould qbecome
qinfected qis qminimized q(Fig. q1–1). qPas- qsive qimmunity qis
qprovided qwhen qa qperson qreceives qselect qan- qtibodies,
qusually qvia qthe qadministration qof qimmune qglobulin q(IG),
qafter qexposure qto qan qinfective qagent. qThis qimmunity qis
qtemporary qand qrequires qthe qpatient qto qpresent qpost-
exposure; qthe qprotection qprovided qby qIG qusually qstarts
qwithin qhours qof qreceiving qthe qdoses qand qlasts qa qnumber qof
qmonths. qThe quse qof qvaccines qto qproduce qlasting qdisease
qprotection qis qpreferred qto qpassive qimmunization qthrough
qthe quse qof qIG. qAnother qexam- qple qof qpassive qimmunity qis
qthe qacquisition qof qdisease qprotec- qtion qprovided qfrom
qmother qto qunborn qchild qvia qthe qplacenta. qSecondary
qprevention qmeasures qinclude qactivities qprovided qto
qidentify qand qtreat qasymptomatic qpersons qwho qhave qrisk qfac-
qtors qfor qa qgiven qdisease qor qin qpreclinical qdisease. qExamples
qin- qclude qscreening qexaminations qfor qpreclinical
qevidence qof qcancer, qsuch qas qmammography qand qcervical
qexamination qwith q a qPapanicolaou qtest. qOther qexamples qof
qsecondary qprevention qactivities qinclude qscreening qfor
qclinical qconditions qwith qa qpro- qtracted qasymptomatic
qperiod, qsuch qas qa qblood qpressure qmeas- qurement qto qdetect
qhypertension qand qa qlipid qprofile qto qdetect
qhyperlipidemia q(Table q1–1).
See qfull qcolor qimages qof qthis qtopic
qon qDavisPlus qat
qhttp://davisplus.fadavis.com q|
qKeyword: qFitzgerald
Tertiary qprevention qmeasures qare qpart qof qthe
qmanagement qof qan qestablished qdisease. qThe qgoal qis qto
qminimize qdisease- qassociated qcomplications qand qthe
qnegative qhealth qeffects qof qthe qconditions qto qthe qpatient.
qExamples qinclude qmedications qand qlifestyle qmodification
qto qnormalize qblood qglucose qlevels qin qindividuals qwith
qdiabetes qmellitus qand qin qconjunction qwith qthe qtreatment qof
qheart qfailure, qaimed qat qimproving qor qmini- qmizing
qdisease-related qsymptoms.
DISCUSSION q SOURCES
http://www.cdc.gov/excite/skincancer/mod13.htm, Centers for
, 10. When qadvising qa qpatient qabout qinjectable qinfluenza C. The q drugs q are q active q only q against q influenza q B.
qim- qmunization, qthe qnurse qpractitioner q(NP) D. The quse qof qthese qmedications qis qan qacceptable
qconsiders qthe qfollowing qabout qthe quse qof qthis qalter- qnative qto qinfluenza qvaccine.
qvaccine:
A. Its quse qis qnot qrecommended qin qsickle qcell qanemia.
B. Its quse qis qlimited qto qchildren qolder qthan q2 qyears.
C. Its q use q is q limited q due q to q containing q live q virus.
D. Its quse qis qrecommended qfor qvirtually qall qmembers
qof qthe qpopulation.
11. A qmiddle-aged qman qwith qchronic qobstructive
qpul- qmonary qdisease qwho qis qabout qto qreceive
qinjectable qin- qfluenza qvaccine qshould qbe
qadvised qthat:
A. it qis qmore qthan q90% qeffective qin qpreventing
qinfluenza.
B. its quse qis qcontraindicated qin qthe qpresence qof
qpsoriasis qvulgaris.
C. localized qreactions qsuch qas qsoreness qand qredness
qat qthe qsite qof qthe qimmunization qare qfairly
qcommon.
D. a qshort, qintense, qflulike qsyndrome qtypically
qoccurs qafter qimmunization.
12. A q44-year-old qwoman qwith qasthma qpresents qasking
qfor qa q“flu qshot.” qShe qis qseen qtoday qfor qan qurgent qcare
qvisit, qis qdiagnosed qwith qa qlower qurinary qtract
qinfection, qand qis qprescribed qtrimethoprim-
sulfamethoxazole. qShe qis qwithout qfever qor
qgastrointestinal qupset qwith qstable qrespiratory
qstatus. qYou qinform qher qthat qshe:
A. should qreturn qfor qthe qimmunization qafter
qcomplet- qing qher qantibiotic qtherapy.
B. would qlikely qdevelop qa qsignificant qreaction qif
qimmu- qnized qtoday.
C. can q receive q the q immunization q today.
D. is qnot qa qcandidate qfor qany qform qof qinfluenza
qvaccine.
13. Which qof qthe qfollowing qstatements qbest qdescribes
qamantadine qor qrimantadine quse qin qthe qcare qof
qpatients qwith qor qat qrisk qfor qinfluenza?
A. Significant qresistance qto qselect qstrains qof
qinfluenza qlimits qthe qusefulness qof qthese
qmedications.
B. The qprimary qaction qof qthese qtherapies qis qin
qprevent- qing qinfluenza qA qduring qoutbreaks.
C. These q therapies q are q active q against q influenza q A q and
q B.
D. The quse qof qthese qproducts qis qan qacceptable
qalternative qto qinfluenza qvaccine.
14. Which qof qthe qfollowing qstatements qbest qdescribes
qzanamivir q(Relenza) qor qoseltamivir q(Tamiflu) quse qin
qthe qcare qof qpatients qwith qor qat qrisk qfor qinfluenza?
A. Initiation qof qtherapy qearly qin qacute qinfluenza
qillness qcan qhelp qminimize qthe qseverity qof qdisease
qwhen qthe qillness qis qcaused qby qa qnonresistant
qviral qstrain.
B. The qprimary qindication qis qin qpreventing qinfluenza
qA qduring qoutbreaks.
